Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs

NCT06291987 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06291987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Recruiting
Start date
September 19, 2024
Completion date
May 31, 2029
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasms